Skip to content

Homoeopathic medicine in treatment of dysthymia

AN INTERVENTIONAL STUDY TO EVALUATE THE ROLE OF INDIVIDUALIZED HOMOEOPATHIC MEDICINE IN ADULTS WITH DYSTHYMIC DISORDER USING CORNELL DYSTHYMIA RATING SCALE - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/04/107827
Enrollment
36
Registered
2026-04-07
Start date
Unknown
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F341- Dysthymic disorder

Interventions

Intervention1: Individualized Homoeopathic medicine: Administering indicated homoeopathic medicine for a period of 3 months. The potency (30C or 200C,1M, 10M, 50M, Fifty millesimal potency) will be ch

Sponsors

National Institute of Homoeopathy, Delhi.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All the sexes of the age group 18-65 years irrespective of their socio-economic status will be included. Participants must have a clinical diagnosis of Dysthymic Disorder based on standardized ICD 11 (International Classification of Diseases) diagnostic criteria. Participants who have a Cornell Dysthymia Rating Scale (CDRS) score between 20 and 59, indicating mild to moderate dysthymia will be included.

Exclusion criteria

Exclusion criteria: 1.Participants with other severe psychiatric disorders (bipolar disorder schizophrenia) will be excluded from the study. 2.Participants who show evidence of high suicide risk as assessed by the Suicide Behaviours Questionnaire Revised (SBQ-R) will be excluded from the study. Specifically Individuals scoring at or above the established cutoff score for their population (more than or equal to 7 for the general population, more than or equal to for psychiatric inpatients) indicating significant suicidal ideation or behaviour. 3. Individuals with substance abuse issues will be excluded. 4. Medical or neurological conditions that may influence mood symptoms or interfere with the assessment or treatment of dysthymia such as severe cardiovascular disease, endocrine disorders (hypothyroidism) or neurological illnesses ( Parkinson s disease multiple sclerosis) will be excluded. 5. pregnant women and lactating mother will be excluded from the study. 6. Patients who are under any modern psychiatric medication. 7.Patients who develop symptoms of psychosis in between the study will be referred to a psychiatrist as per the patient s requirement. 8.Patients with organic mental disease will be excluded from the study.

Design outcomes

Primary

MeasureTime frame
Cornell Dysthymia Rating Scale (CDRS) scoreTimepoint: assess at baseline and at the end of 3 months

Secondary

MeasureTime frame
Modified Naranjo Criteria (MONARCH) score.Timepoint: At the end of treatment (3rd month)

Countries

India

Contacts

Public ContactGrace Thokchom

National Institute of Homoeopathy, Delhi.

gracethokchom191@gmail.com9378076013

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026